Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of HPV Prevalence in Pairs of Cervical and Urine Samples from the Same Woman

  • Kim, Dong Hyeok (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Jin, Hyunwoo (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Lee, Kyung Eun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
  • Received : 2021.02.18
  • Accepted : 2021.03.29
  • Published : 2021.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

The main cause of cervical cancer is a persistent infection with high-risk human papillomavirus (HR-HPV). Cervical cancer is reported as a preventable cancer in more than 80% of cases with early diagnosis and appropriate treatment. Papanicolaou test (Pap test) has been a global strategy to prevent cervical cancer, and recently, HPV test has been reported to be effective against cervical cancer and precancerous lesions. However, pelvic examinations give patients anxiety, discomfort, pain, distress, and psychological stress. HPV test via a urine sample caused less physical and psychological stress and more advantage than the Pap test. Therefore, it is necessary to study the usefulness of the HPV test for easy-to-collect urine samples. A total of 220 samples were collected from a pair of cervical and urine samples from 110 women and only 108 pairs of samples out of 110 were used because 2 cases were not amplified by β-globin. Among 108 pairs of cervical and urine samples, the prevalence of HPV was 37.0% (40/108) in cervical samples, 34.3% (37/108) in urine samples and HR-HPV was 22.2% (24/108) in cervical samples, 18.5% (20/108) in urine samples. In this study, urine samples showed a lower positive rate of HPV than cervical samples. There were many variables that could affect the condition of the urine sample. However, the HR-HPV agreement rate of the cervix and urine samples was 94.44% and the Kappa value was 0.823, which was "almost perfect". Through these results showed the significance of cervical cancer screening using a urine sample. Cervical screening is crucial, as cervical cancer can be prevented in more than 90% of cases. Urine samples collected by non-invasive methods may have the potential advantage of increasing acceptance of cervical cancer screening. Therefore, it is necessary to develop a new cervical cancer screening strategy using urine samples through further study based on the results of this study.

Keywords

References

  1. Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, Vedder JEM, Schuurman R, van den Brule AJC, van der Linden HC, Hinrichs JWJ, Molijn A, Hoogduin KJ, van Hemel BM, de Kok IMCM. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Med. 2019. 17: 228. https://doi.org/10.1186/s12916-019-1460-0
  2. Asciutto KC, Ernstson A, Forslund O, Borgfeldt C. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. J Clin Virol. 2018. 101: 69-73. https://doi.org/10.1016/j.jcv.2018.02.002
  3. Bernal S, Palomares JC, Artura A, Parra M, Cabezas JL, Robles A, Martin Mazuelos E. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test. J Clin Virol. 2014. 61: 548-552. https://doi.org/10.1016/j.jcv.2014.10.001
  4. Cho HW, Ouh YT, Hong JH, Min KJ, So KA, Kim TJ, Paik ES, Lee JW, Moon JH, Lee JK. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. J Virol Methods. 2019. 269: 77-82. https://doi.org/10.1016/j.jviromet.2019.04.012
  5. Colpani V, Soares Falcetta F, Bacelo Bidinotto A, Kops NL, Falavigna M, Serpa Hammes L, Schwartz Benzaken A, Kalume Maranhao AG, Domingues CMAS, Wendland EM. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis. PLoS One. 2020. 15: e0229154. https://doi.org/10.1371/journal.pone.0229154
  6. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006. 119: 1095-1101. https://doi.org/10.1002/ijc.21955
  7. Frati ER, Martinelli M, Fasoli E, Colzani D, Bianchi S, Binda S, Olivani P, Tanzi E. HPV Testing from Dried Urine Spots as a Tool for Cervical Cancer Screening in Low-Income Countries. Biomed Res Int. 2015. 2015: 283036.
  8. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res Treat. 2020. 52: 335-350. https://doi.org/10.4143/crt.2020.206
  9. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015. 136: 178-182. https://doi.org/10.1016/j.ygyno.2014.12.022
  10. Khunamornpong S, Settakorn J, Sukpan K, Lekawanvijit S, Katruang N, Siriaunkgul S. Comparison of Human Papillomavirus Detection in Urine and Cervical Samples Using High-Risk HPV DNA Testing in Northern Thailand. Obstet Gynecol Int. 2016. 2016: 6801491.
  11. Kim MA, Han GH, Kim JH, Seo K. Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview. J Korean Med Sci. 2018. 33: e331. https://doi.org/10.3346/jkms.2018.33.e331
  12. Lim MC, Lee DH, Hwang SH, Hwang NR, Lee B, Shin HY, Jun JK, Yoo CW, Lee DO, Seo SS, Park SY, Joo J. Comparison of the Abbott RealTime High Risk HPV test and the Roche cobas 4800 HPV test using urine samples. J Virol Methods. 2017. 243: 74-79. https://doi.org/10.1016/j.jviromet.2017.01.020
  13. Nilyanimit P, Chansaenroj J, Karalak A, Laowahutanont P, Junyangdikul P, Poovorawan Y. Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples using the HPV GenoArray Diagnostic assay. PeerJ. 2017. 5: e3910. https://doi.org/10.7717/peerj.3910
  14. Pattyn J, Van Keer S, Biesmans S, Ieven M, Vanderborght C, Beyers K, Vankerckhoven V, Bruyndonckx R, Van Damme P, Vorsters A. Human papillomavirus detection in urine: Effect of a first-void urine collection device and timing of collection. J Virol Methods. 2019. 264: 23-30. https://doi.org/10.1016/j.jviromet.2018.11.008
  15. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014. 383: 524-532. https://doi.org/10.1016/S0140-6736(13)62218-7
  16. Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am. 2007. 34: 739-760. https://doi.org/10.1016/j.ogc.2007.09.004
  17. Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM. Women's experience with home-based self-sampling for human papillomavirus testing. BMC Cancer. 2015. 15: 849. https://doi.org/10.1186/s12885-015-1804-x
  18. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst. 2002. 94: 193-204. https://doi.org/10.1093/jnci/94.3.193
  19. van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG. 2012. 119: 699-709. https://doi.org/10.1111/j.1471-0528.2011.03228.x
  20. Vergara N, Balanda M, Vidal D, Roldan F, S Martin H, Ramirez E. Detection and quantitation of human papillomavirus DNA in peripheral blood mononuclear cells from blood donors. J Med Virol. 2019. 91: 2009-2015. https://doi.org/10.1002/jmv.25551
  21. Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences among non-attendees to cervical screening. Gynecol Oncol. 2014. 135: 487-494. https://doi.org/10.1016/j.ygyno.2014.09.019
  22. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis. 2012. 31: 627-640. https://doi.org/10.1007/s10096-011-1358-z
  23. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, De Coster I, Ieven M, Van Damme P. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis. 2014. 33: 2005-2014. https://doi.org/10.1007/s10096-014-2147-2
  24. World Health Organization 2020. Human Papillomavirus (HPV) and Cervical Cancer 2020.